(04-26-2021, 09:10 AM)EmuAGR escribió: Y ANLIUM, pero la semana pasada me salió ardiendo el portátil.

(04-26-2021, 04:29 PM)Yumichan escribió:

(04-26-2021, 09:10 AM)EmuAGR escribió: Y ANLIUM, pero la semana pasada me salió ardiendo el portátil.

https://www.youtube.com/watch?v=PJGpsL_XYQI

(04-26-2021, 06:10 AM)Reboot escribió: ANLIUM pero tras estar un año con el Gboard me vuelvo a mi querido y difunto swype.

Ningún teclado deslizante funciona mejor.

Cita:As Bert points out in his article, to ensure the immune system does not attack the foreign mRNA, every uracil (the letter U in the RNA sequence) is replaced by 1-methyl-3’-pseudouridylyl (canonical name is N1-Methylpseudouridine). Note that pseudouridylyl is phonetically similar to the more common pseudouridine, but chemically quite different thanks to the addition of a methyl group.3 1-methyl-3’-pseudouridylyl can be purchased from TriLink and JenaBiosciences, for example, but both BioNTech and Moderna likely license the molecule from the University of Pennsylvania4 and produce it themselves.
The pseudouridylyl replacement is a neat little trick to fly under the radar of the immune system. However, more work is needed to make the mRNA work as a vaccine. mRNA is not very stable, and is especially prone to damage at the ends. If you lose the first and last word of a sentence its meaning may be lost entirely. The same can happen here and the vaccine would not work anymore.
To protect the “beginning” of the mRNA statement, a 5’ cap is added. This can be done co-transcriptionally, in the same process step as when the rest of the mRNA is assembled, or post-transcriptionally, in a separate process step. To do so co-transcriptionally, a 5’ cap analog is added to the reaction mixture and incorporated by the polymerase when it reads a specific initiator sequence. There is only one vendor for this analog: TriLink and its partner tebu-bio for the European market. Post-transcriptionally it can be done using a mRNA Cap 2′-O-Methyltransferase and the vaccinia capping enzyme (VCE).5 The co-transcriptional method is generally more suitable for industrial processes as there is no need for an additional post-purification and it is faster since it works in one step. In their July 2020 investor update BioNTech refers to usings TriLinks trinucleotide cap and hence this is likely part of the production method of the approved vaccine. Ultimately, the cap analogue or the VCE can drive cost and present bottlenecks if production is not increased accordingly.6
To protect the end of the mRNA we add a poly(A) tail to the message either by encoding it in the DNA template or using a Poly(A)Polymerase. Both BioNTech and Moderna are using the faster and convenient DNA template approach.